ID   PER.C6 TetR
AC   CVCL_A7ME
DR   Wikidata; Q107116656
WW   Info; EMA; -; https://www.ema.europa.eu/en/documents/assessment-report/covid-19-vaccine-janssen-epar-public-assessment-report_en.pdf
CC   Group: Vaccine production cell line.
CC   From: Johnson & Johnson Janssen; Beerse; Belgium.
CC   Biotechnology: Used for the production of the Janssen SARS-CoV-2 (COVID-19) vaccine (Trade name: Ad26.COV2.S) (DrugBank=DB15857). In the context of the vaccine production, the tetR repressor blocks the expression of the SARS-CoV-2 spike protein gene during production of the recombinant adenoviral vector, thereby optimising vector production.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P04483; Escherichia coli Tn10 tetR.
CC   Transformant: NCBI_TaxID; 28285; Adenovirus 5 (Note=E1).
CC   Derived from site: In situ; Fetal eye, retina; UBERON=UBERON_0003072.
CC   Cell type: Retinoblast; CL=CL_4023129.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_G704 ! PER.C6
SX   Sex unspecified
AG   18FW
CA   Transformed cell line
DT   Created: 20-05-21; Last updated: 10-04-25; Version: 10
//